Side-by-side · Research reference

ThymalinvsVIP

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticAUTO-DRAFTED12/40 cited

BPhase 3HUMAN-REVIEWED9/42 cited

Thymalin

Immune restorer · Russian peptide bioregulator

5–10 mgPer cycle doseKhavinson 2002

HumanMechanisticKhavinson 2002

HoursHalf-life (est)

IM · Daily for 5–10 days · 1-2×/year

VIP

Neuropeptide · VPAC1/VPAC2 Agonist · Emergency Use Authorization (COVID-19 ARDS)

IntravenousPrimary routeBrown 2023

ARDSLead indicationUdupa 2025

Phase 3Development stage

IV infusion · Inhaled (investigational)Brown 2023 Boesing 2022

01Mechanism of Action

Parameter

Thymalin

VIP

Primary target

T-cell precursors + thymus-axis maturation pathwayKhavinson 2002

VPAC1 and VPAC2 G-protein-coupled receptorsUdupa 2025

Pathway

Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002

VIP → VPAC1/VPAC2 activation → cAMP elevation → Pulmonary vasodilation + epithelial protection

Downstream effect

Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002

Anti-inflammatory cytokine modulation, alveolar-capillary membrane stabilization, pulmonary smooth muscle relaxation, reduced neutrophil infiltration

Feedback intact?

—

Yes — exogenous VIP acts as physiological agonist

Origin

Polypeptide fraction isolated from calf thymus extractKhavinson 2002

Endogenous 28-amino-acid neuropeptide; synthetic analogue (aviptadil) identical to natural VIP

Antibody development

—

02Dosage Protocols

Parameter

Thymalin

VIP

Standard dose

5–10 mg / day IM × 5–10 daysKhavinson 2002

—

Frequency

Once daily during cycle

—

Lower / starter dose

2.5 mg / day

—

Evidence basis

Russian clinical + in vitroKhavinson 2002

Phase 3 RCT (TESICO)Brown 2023

816-patient randomized controlled trial in COVID-19 ARDS.

Duration

5–10 day cycles, 1–2× per year

—

Reconstitution

Saline or bacteriostatic water

Lyophilized powder reconstituted with sterile diluent per protocol

Timing

Morning preferred

—

Half-life

Hours (estimated)

~2 minutes (plasma)

Rapid clearance necessitates continuous infusion.

Intravenous (ARDS protocol)

—

60–90 mcg/kg/day via continuous infusion

TESICO trial protocol for COVID-19 ARDS.

Infusion duration

—

12-hour continuous IV infusion dailyBrown 2023

Inhaled (investigational)

—

Variable dosing under clinical trial protocolsBoesing 2022

Delivered via nebulizer for direct pulmonary deposition.

Treatment duration

—

3–14 days (acute ARDS)

04Side Effects & Safety

Parameter

Thymalin

VIP

Injection site reaction

Mild erythema at IM site

—

Allergic reaction

Rare hypersensitivity to bovine-derived polypeptide

—

Autoimmune flare

Theoretical risk in active autoimmune disease

—

Long-term safety

Limited Western data

—

Pregnancy / OB

Avoid

—

Hypotension

—

Transient vasodilation-related blood pressure drop

Tachycardia

—

Reflex tachycardia secondary to vasodilation

Infusion site reactions

—

Erythema, phlebitis (IV administration)

GI symptoms

—

Nausea, diarrhea (VIP is endogenous GI peptide)

Overall tolerability

—

Well-tolerated in Phase 3 trials; adverse event profile comparable to placebo

Absolute Contraindications

Thymalin

·Pregnancy / breastfeeding
·Bovine protein hypersensitivity

VIP

·Known hypersensitivity to aviptadil or formulation components

Relative Contraindications

Thymalin

·Active autoimmune disease
·Concurrent immunosuppressant therapy

VIP

·Severe hypotension or shock states (monitor blood pressure)
·Pregnancy — insufficient safety data

05Administration Protocol

Parameter

Thymalin

VIP

1. Reconstitution

Add 1–2 mL saline or bacteriostatic water per 10 mg vial.

Reconstitute lyophilized aviptadil powder with sterile diluent per manufacturer protocol. Inspect solution for particulates — should be clear and colorless.

2. Injection site

Intramuscular — deltoid or gluteal. Rotate sites.

Administer as continuous 12-hour intravenous infusion via central or peripheral line. Use infusion pump for precise dosing (60–90 mcg/kg/day divided over infusion duration).

3. Timing

Morning preferred during cycle.

Monitor blood pressure, heart rate, and oxygenation continuously during first infusion. Assess for hypotension and adjust infusion rate if needed.

4. Storage

Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.

Deliver via jet or mesh nebulizer per clinical trial protocol. Patient seated upright, normal tidal breathing for 10–15 minutes.

5. Needle

23–25G, 25–38 mm IM needle.

Store lyophilized powder at 2–8 °C, light-protected. Reconstituted solution: use immediately or within 24 hours if refrigerated.

06Stack Synergy

Thymalin

+ Thymosin α-1

Moderate

View Thymosin α-1 →

Thymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.

Thymalin: 5–10 mg IM · daily × 7 days
Thymosin α-1: 1.6 mg SQ · 2× weekly during the cycle
Primary benefit: Broad thymic restoration + targeted immune activation

Khavinson 2002 Camerini 2001

VIP

— no documented stacks